BioSpace News Archive

Stealth BioTherapeutics Corp announced that on January 4, 2022, it received a letter from The Nasdaq Stock Market LLC, notifying the Company that it is currently not in compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5450.

Assembly Biosciences, Inc. announced grants of stock options to two new employees to purchase an aggregate of 7,000 shares of the Company’s common stock with an exercise price of $2.45 per share, the closing price of Assembly Bio’s common stock on January 3, 2022.

The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular support networks.

Royalty Pharma Extends Capital to Cytokinetics to Support the Commercial Launch of Omecamtiv Mecarbil and the Further Development of Aficamten Royalty Pharma Purchases Royalties on Future Sales of Aficamten.

Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the management team will participate in the H.C. Wainwright BioConnect Virtual Conference from January 10th to January 13th.

Fulcrum Therapeutics, Inc. today announced the grant of an inducement award outside of the Company’s 2019 Stock Incentive Plan to Esther Rajavelu, the Company’s newly appointed Chief Financial Officer.

Treace Medical Concepts, Inc. today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 4:30 p.m. Eastern Time.

Mersana Therapeutics, Inc. today provided its strategic priorities and anticipated milestones for 2022.

Icosavax, Inc. today provided a corporate update and shared anticipated milestones for 2022.

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be speaking at the HC Wainwright BioConnect Conference, to be held virtually from 10-13 January 2022.